↓ Skip to main content

High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos

Overview of attention for article published in Stem Cell Research & Therapy, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

blogs
1 blog
twitter
6 X users

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
91 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos
Published in
Stem Cell Research & Therapy, June 2017
DOI 10.1186/s13287-017-0561-y
Pubmed ID
Authors

Jinpei Ye, Nicola Bates, Despina Soteriou, Lisa Grady, Clare Edmond, Alex Ross, Alan Kerby, Philip A. Lewis, Tope Adeniyi, Ronnie Wright, Kay V. Poulton, Marcus Lowe, Susan J. Kimber, Daniel R. Brison

Abstract

Human embryonic stem cells (hESCs) hold tremendous promise for cell replacement therapies for a range of degenerative diseases. In order to provide cost-effective treatments affordable by public health systems, HLA-matched allogeneic tissue banks of the highest quality clinical-grade hESCs will be required. However only a small number of existing hESC lines are suitable for clinical use; they are limited by moral and ethical concerns and none of them apply Good Manufacturing Practice (GMP) standards to the earliest and critical stages of gamete and embryo procurement. We thus aimed to derive new clinical grade hESC lines of highest quality from fresh surplus GMP grade human embryos. A comprehensive screen was performed for suitable combinations of culture media with supporting feeder cells or feeder-free matrix, at different stages, to support expansion of the inner cell mass and to establish new hESC lines. We developed a novel two-step and sequential media system of clinical-grade hESC derivation and successfully generated seven new hESC lines of widely varying HLA type, carefully screened for genetic health, from human embryos donated under the highest ethical and moral standards under an integrated GMP system which extends from hESC banking all the way back to gamete and embryo procurement. The present study, for the first time, reports the successful derivation of highest-quality clinical-grade hESC lines from fresh poor-quality surplus human embryos generated in a GMP-grade IVF laboratory. The availability of hESC lines of this status represents an important step towards more widespread application of regenerative medicine therapies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 91 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 19%
Researcher 15 16%
Student > Ph. D. Student 15 16%
Student > Bachelor 11 12%
Student > Doctoral Student 2 2%
Other 3 3%
Unknown 28 31%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 27 30%
Agricultural and Biological Sciences 13 14%
Medicine and Dentistry 5 5%
Nursing and Health Professions 3 3%
Neuroscience 2 2%
Other 11 12%
Unknown 30 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2017.
All research outputs
#3,148,717
of 22,979,862 outputs
Outputs from Stem Cell Research & Therapy
#266
of 2,428 outputs
Outputs of similar age
#60,340
of 317,195 outputs
Outputs of similar age from Stem Cell Research & Therapy
#5
of 61 outputs
Altmetric has tracked 22,979,862 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,428 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,195 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.